Effective leadership in an innovation-driven company isn't about being 'tough' but 'demanding' of high standards. The Novonesis CEO couples this with an explicit acceptance of failure as an inherent part of R&D, stressing the need to 'fail fast' and learn from it.

Scientist-founders often believe one more experiment will prove their hypothesis. To succeed as a CEO, they must shift from scientific curiosity to ruthless capital discipline, killing unviable programs and building a team that challenges ideas, not just executes them.

The industry's costly drug development failures are often attributed to clinical issues. However, the root cause is frequently organizational: siloed teams, misaligned incentives, and hierarchical leadership that stifle the knowledge sharing necessary for success.

A CEO's primary role differs fundamentally based on company type. In an asset-centric biotech, the CEO must act as a hands-on program manager, micromanaging execution. In a platform company, the CEO must be deeply embedded in the science to predict and leverage the technology's long-term trajectory.

True innovation requires leaders to adopt a venture capital mindset, accepting that roughly nine out of ten initiatives will fail. This high tolerance for failure, mirroring professional investment odds, is a prerequisite for the psychological safety needed for breakthrough results.

The traditional pharma leadership model focused on minimizing risk through tight, linear control is no longer competitive. The future requires a shift to agile coordination, allowing leaders to reallocate priorities quickly in a data-driven, connected way.

Stelios Papadopoulos argues that major drug breakthroughs are stochastic events driven by individual intuition, luck, and counterintuitive thinking, not predictable R&D systems. He states that if discovery could be systematized by AI or process, no company would have an edge.

R&D departments in large pharmaceutical companies often resist repurposing projects. Their leaders are rewarded for discovering new chemical entities, not for finding new applications for existing drugs, creating an internal funding barrier that business units must overcome.

The ambition to be a CEO isn't just about leadership; it's a practical blend of ego, a need for control, and financial motivation. Critically, it stems from a deep-seated belief in one's own judgment and risk appetite, especially during pivotal market shifts that require bold, swift action.